SOPH

+ Watchlist + Portfolio

SOPHiA GENETICS SA

Recurring revenue Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.03
52-Week Range: $3.75 – $8.98
Market Cap: $686.98M
P/E (TTM): —
EPS (TTM): -1.16
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 8.27
PEG Ratio: —
Return on Equity: -101.22%
Return on Assets: -24.52%
Gross Margin: 66.63%
Operating Margin: -86.03%
Profit Margin: -93.86%
Current Ratio: 2.69
Debt/Equity: 0.74
Total Debt: $61.83M
Free Cash Flow: $-25.66M
Revenue Growth: 27.20%
Earnings Growth: —
Enterprise Value: $641.14M

SOPH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$47.56M	$62.37M	$65.17M	$77.27M
Cost of Revenue	$16.31M	$19.46M	$21.24M	$25.19M
Gross Profit	$31.25M	$42.91M	$43.94M	$52.08M
Research & Development	$35.37M	$36.97M	$34.37M	$34.22M
Selling, General & Admin	$84.08M	$77.98M	$73.21M	$86.07M
Operating Expenses	$119.08M	$117.74M	$110.50M	$122.98M
Operating Income	-$87.82M	-$74.83M	-$66.57M	-$70.91M
EBITDA	-$81.38M	-$69.57M	-$50.76M	-$63.40M
Pretax Income	-$87.58M	-$78.50M	-$61.27M	-$77.49M
Income Tax	-$136.00K	$486.00K	$1.22M	$1.51M
Net Income	-$87.45M	-$78.98M	-$62.49M	-$79.00M
Diluted EPS	-1.36	-1.22	-0.95	-1.17
Diluted Shares	64.10M	64.75M	65.78M	67.54M

SOPH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$161.31M	$123.25M	$80.23M	$70.29M
Receivables	$8.05M	$15.21M	$8.69M	$16.52M
Inventory	$5.16M	$6.48M	$5.87M	$6.35M
Current Assets	$196.25M	$148.05M	$99.41M	$99.08M
Total Assets	$243.84M	$206.16M	$155.31M	$163.03M
Current Liabilities	$26.81M	$35.62M	$26.80M	$50.53M
Long-Term Debt	—	—	$13.24M	$47.73M
Total Debt	$16.74M	$18.60M	$30.03M	$63.02M
Total Liabilities	$43.71M	$54.71M	$58.82M	$115.89M
Retained Earnings	-$298.80M	-$377.78M	-$440.28M	-$519.28M
Shareholders' Equity	$200.13M	$151.44M	$96.49M	$47.15M
Working Capital	$169.44M	$112.43M	$72.60M	$48.55M

SOPH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$70.09M	-$53.22M	-$44.52M	-$35.89M
Capital Expenditure	-$10.38M	-$9.23M	-$8.18M	-$8.62M
Free Cash Flow	-$80.47M	-$62.45M	-$52.69M	-$44.51M
Depreciation & Amortisation	$5.57M	$8.34M	$8.60M	$9.53M
Stock-Based Compensation	$13.61M	$15.24M	$16.49M	$16.20M
Investing Cash Flow	$41.97M	$12.97M	-$4.75M	-$8.67M
Financing Cash Flow	-$1.57M	-$2.82M	$9.86M	$30.18M
Dividends Paid	—	$0.00	$0.00	$0.00
Net Change in Cash	-$29.69M	-$43.07M	-$39.41M	-$14.39M

SOPH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$17.78M	$18.32M	$19.46M	$21.71M	$21.69M	$23.31M
Cost of Revenue	$5.57M	$6.05M	$6.55M	$7.01M	$6.94M	$8.25M
Gross Profit	$12.21M	$12.27M	$12.91M	$14.69M	$14.75M	$15.06M
Research & Development	$9.12M	$8.49M	$8.07M	$8.54M	$9.46M	$8.73M
Selling, General & Admin	$19.13M	$22.34M	$22.56M	$22.04M	$22.57M	$26.39M
Operating Expenses	$28.24M	$30.76M	$30.77M	$33.21M	$32.03M	$35.11M
Operating Income	-$16.04M	-$18.49M	-$17.86M	-$18.52M	-$17.28M	-$20.05M
EBITDA	-$13.93M	-$18.72M	-$15.29M	-$15.46M	-$14.65M	-$17.75M
Pretax Income	-$16.88M	-$21.65M	-$19.38M	-$19.57M	-$19.07M	-$22.28M
Income Tax	$503.00K	$762.00K	$642.00K	-$395.00K	$253.00K	$78.00K
Net Income	-$17.39M	-$22.41M	-$20.02M	-$19.18M	-$19.32M	-$22.36M
Diluted EPS	-0.26	-0.33	-0.30	-0.28	-0.27	-0.30
Diluted Shares	66.38M	67.32M	67.79M	68.50M	71.14M	73.84M

SOPH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$68.53M	$94.82M	$81.61M	$70.29M	$65.39M	$107.67M
Receivables	$10.70M	$9.51M	$8.46M	$16.52M	$14.31M	$14.11M
Inventory	$5.05M	$6.22M	$6.68M	$6.35M	$7.09M	$7.08M
Current Assets	$90.05M	$117.03M	$103.48M	$99.08M	$95.81M	$137.29M
Total Assets	$146.72M	$177.62M	$163.46M	$163.03M	$157.00M	$198.36M
Current Liabilities	$28.94M	$34.48M	$36.93M	$50.53M	$46.59M	$51.08M
Long-Term Debt	$13.32M	$47.47M	$47.58M	$47.73M	$47.84M	$48.00M
Total Debt	$30.13M	$63.81M	$63.37M	$63.02M	$62.42M	$61.83M
Total Liabilities	$61.11M	$100.93M	$102.77M	$115.89M	$111.31M	$115.24M
Retained Earnings	-$457.66M	-$480.08M	-$500.10M	-$519.28M	-$538.60M	-$560.95M
Shareholders' Equity	$85.61M	$76.69M	$60.69M	$47.15M	$45.69M	$83.12M
Working Capital	$61.11M	$82.55M	$66.55M	$48.55M	$49.22M	$86.21M

SOPH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$10.75M	-$8.21M	-$8.79M	-$8.14M	-$15.12M	-$7.69M
Capital Expenditure	-$1.49M	-$1.98M	-$2.69M	-$2.46M	-$2.87M	-$2.70M
Free Cash Flow	-$12.24M	-$10.19M	-$11.48M	-$10.60M	-$17.99M	-$10.39M
Depreciation & Amortisation	$2.30M	$2.37M	$2.42M	$2.44M	$2.75M	$2.91M
Stock-Based Compensation	$3.83M	$4.36M	$4.15M	$3.87M	$3.31M	$4.49M
Investing Cash Flow	-$1.04M	-$1.55M	-$2.58M	-$3.50M	-$2.58M	-$2.47M
Financing Cash Flow	-$990.00K	$33.54M	-$1.99M	-$385.00K	$13.04M	$53.99M
Dividends Paid	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$12.78M	$23.77M	-$13.36M	-$12.02M	-$4.66M	$43.83M

Market Snapshot

About

SOPHiA GENETICS is a healthcare technology company that applies artificial intelligence and data analytics to genomic and multimodal data. The company operates a cloud-based platform that helps hospitals, laboratories, and biopharma institutions analyze complex genomic information for clinical diagnostics and drug development. SOPHiA GENETICS focuses on oncology, rare diseases, and other genetic conditions.